Cases & Deals

BioMarin expands rare disease oligonucleotide therapeutic patent portfolio following worldwide settlement with Sarepta

Clients BioMarin Pharmaceutical Inc.

Jones Day represents BioMarin Pharmaceutical Inc. in prosecution of patent portfolio directed to oligonucleotide therapeutic agents for treatment of rare genetic diseases, including Duchenne Muscular Dystrophy and Becker Muscular Dystrophy. BioMarin recently entered into a worldwide settlement with Sarepta regarding patent disputes related to this portfolio.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.